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Comprehensive characterization of the 
patient-derived xenograft and the paralleled 
primary hepatocellular carcinoma cell line
Phyllis F. Y. Cheung1,2, Chi Wai Yip1,3,4, Linda W. C. Ng1, Kwok Wai Lo2, Chit Chow2, Kui Fat Chan5, Tan To Cheung3 
and Siu Tim Cheung1,6* 
Abstract 
Background: Hepatocellular carcinoma (HCC) is an aggressive cancer with high mortality and morbidity worldwide. 
The limited clinically relevant model has impeded the development of effective HCC treatment strategy. Patient-
derived xenograft (PDX) models retain most of the characteristics of original tumors and were shown to be highly 
predictive for clinical outcomes. Notably, primary cell line models allow in-depth molecular characterization and 
high-throughput analysis. Combined usage of the two models would provide an excellent tool for systematic study 
of therapeutic strategies. Here, we comprehensively characterized the novel PDX and the paralleled primary HCC cell 
line model.
Methods: Tumor tissues were collected from HCC surgical specimens. HCC cells were sorted for in vivo PDX and 
in vitro cell line establishment by the expression of hepatic cancer stem cell marker to enhance cell viability and the 
rate of success on subsequent culture. The PDX and its matching primary cell line were authenticated and character-
ized in vitro and in vivo.
Results: Among the successful cases for generating PDXs and primary cells, HCC40 is capable for both PDX and pri-
mary cell line establishment, which were then further characterized. The novel HCC40-PDX and HCC40-CL exhibited 
consistent phenotypic characteristics as the original tumor in terms of HBV protein and AFP expressions. In common 
with HCC40-PDX, HCC40-CL was tumorigenic in immunocompromised mice. The migration ability in vitro and meta-
static properties in vivo echoed the clinical feature of venous infiltration. Genetic profiling by short tandem repeat 
analysis and p53 mutation pattern consolidated that both the HCC40-PDX and HCC40-CL models were derived from 
the HCC40 clinical specimen.
Conclusions: The paralleled establishment of PDX and primary cell line would serve as useful models in comprehen-
sive studies for HCC pathogenesis and therapeutics development for personalized treatment.
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Background
Hepatocellular carcinoma (HCC) is an aggressive solid 
tumor with high mortality and morbidity rate world-
wide [1]. HCC is frequently diagnosed at advanced 
stage and therefore curative treatment is not feasible. 
Chemotherapy only showed marginal efficacy due to the 
highly chemoresistant nature of HCC [2]. Sorafenib, the 
only targeted therapeutic agent for HCC, demonstrated 
only modest improvement in overall survival. Therefore, 
there is an urgent need to elucidate the pathogenesis 
and develop new therapeutic strategies for HCC. How-
ever, the lack of clinically relevant models has impeded 
the development of effective HCC treatment strategy [3].
The major limitation of conventional cell line models is 
their poor predictive power on clinical outcome [3]. This 
Open Access
Cancer Cell International
*Correspondence:  stcheung@surgery.cuhk.edu.hk 
1 Department of Surgery, The Chinese University of Hong Kong, Prince 
of Wales Hospital, Shatin, Hong Kong, China
Full list of author information is available at the end of the article
Page 2 of 11Cheung et al. Cancer Cell Int  (2016) 16:41 
is due to the changes in the biological properties of can-
cer cells during their adaptation to the in  vitro culture 
conditions and long-term culture [4, 5]. Recently, there 
has been increasing interest in the development of PDX 
models for improving the drug development process [6–
9]. Numerous studies showed that the response rates in 
PDX models correlated with those observed in the clinic, 
both for targeted therapeutic agents and for conventional 
cytotoxic drugs [10–16]. More importantly, remarkable 
concordance was demonstrated when comparing the 
responses of individual patients with their correspond-
ing PDX models [15, 17–19]. However, PDX establish-
ment required relatively long period of time (usually 
4–8  month) [20, 21], when compared to primary cell 
line establishment. Therefore, cell line models matching 
to corresponding PDX models would be needed for high 
throughput analysis and functional studies. While PDXs 
reflect the histological and phenotypic characteristics of 
the original tumors, their matching cell lines could be 
genetically manipulated to allow in-depth molecular and 
functional studies and high-throughput drug screening.
Maintaining high viability of the freshly isolated tumor 
cells is a critical parameter for successful establishment 
of PDXs and primary cell lines. Pre-operative procedures 
and hepatocyte isolation often induce extensive necrosis 
and apoptosis and greatly reduce the cell viability. There-
fore, efforts have been made on protocol optimization 
to increase the cell viability and success rate for cancer 
models. Isolating and enriching cancer stem cells (CSC) 
prior to implantation into mice was shown to improve 
engraftment rates [22]. Previously, we showed that 
granulin-epithelin precursor (GEP) was a CSC marker 
in HCC [23], and GEP-expressing cells were resistant to 
anoikis-induced apoptosis [24]. GEP level in tumor speci-
men was positively correlated with the viability of freshly 
isolated hepatocytes and the success rate of subsequent 
primary culture [24]. In addition, tumor-derived sphe-
roids were found to survive better under in vitro condi-
tions, and could generate tumors when implanted into 
mice. Besides, these spheroids are composed of pure 
epithelial cells without non-epithelial lineage cells [25], 
so that fibroblast contamination and outgrowth can be 
minimized. Therefore, we attempted to optimize the pro-
tocol by enriching GEP-expressing cells for PDX and cell 
line establishment. For in vitro cell line establishment, we 
employed our previously optimized protocol [24], as well 
as the tumor-derived spheroid approach to increase the 
success rate.
In present study, we described the establishment of 
a new PDX and matching primary cell line from fresh 
tumor specimen of HCC patient. A novel PDX model, 
HCC40-PDX, and its matching primary cell line, HCC40-
CL, were established from a patient with early-staged 
and moderately differentiated HCC. Both models were 
authenticated by short tandem repeat (STR) analysis and 
they resembled the genetic and biological characteristics 
of the original tumor. These established cancer models in 
early passages would serve as useful tool for studying the 
molecular pathogenesis of HCC and provide a preclinical 
tool for therapeutic trial and design.
Methods
Specimen collection
The study protocol was approved by the Institutional 
Review Board of the University of Hong Kong/Hos-
pital Authority Hong Kong West Cluster (HKU/HA 
HKW IRB). Total of 24 patients who underwent cura-
tive partial hepatectomy or liver transplantation for HCC 
between September 2011 and December 2012 at Queen 
Mary Hospital, Hong Kong, were recruited after written 
informed consent was obtained. Tumors and adjacent 
non-tumor liver tissues were collected from the resected 
specimens. The present data on the characterization of 
HCC40-PDX and HCC40-CL were new data, while part 
of the in  vitro and in  vivo data using freshly isolated 
GEP-expressing cells had been reported in another study 
(Addiitonal file 1: Figure S1) [26].
The HCC40-PDX and HCC40-CL original tumor 
specimen was collected from a 66-year-old Chinese male 
patient who underwent curative partial hepatectomy. The 
tumor was 16.0 cm in diameter with venous infiltration, 
stage II according to the pathological tumor-node-metas-
tasis (pTNM) staging system 2009 version and graded as 
moderately differentiated. The patient was seronegative 
for hepatitis B virus (HBV: HBsAg and HBsAb) and hepa-
titis C virus (HCV: HCVab), and serum α-fetoprotein 
(AFP) 30286 ng/mL. Intrahepatic and extrahepatic recur-
rence were observed, and the overall and disease-free 
survival time were 2.3 and 1.3 months, respectively.
PDX and cell line establishment
Tumor specimen dissociation, spheroid formation and 
the subsequent differentiation into adherent cells, and 
the in  vivo tumorigenicity of patients’ tumors were 
described previously [24, 26]. Briefly, tumor tissues were 
digested into disaggregated cells by collagenase and then 
sorted based on their surface GEP by magnetic cell sort-
ing (Miltenyi Biotec, Bergisch Gladbach, Germany) as 
previously described [23, 26], and the GEP-enriched 
cells were subject to in  vivo PDX and in  vitro cell line 
establishment.
For in  vivo PDX establishment, GEP-enriched cells 
were inoculated subcutaneously into immunocompro-
mised NOD/SCID mice with matrigel (50  %, v/v) (BD 
Biosciences, San Jose, CA). Xenograft tumors were 
harvested and passaged when their diameters reached 
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10 mm. For PDX derived from patient #40, serial xeno-
grafts could be generated for more than 10 passages 
and this line of PDX was designated as HCC40-PDX. 
HCC40-PDX were cryopreserved at different passages in 
freezing medium containing 50 % AMEM, 40 % FBS and 
10  % DMSO, and stored in liquid nitrogen. After thaw-
ing, HCC40-PDX could be propagated in mice without 
noticeable change in growth rate.
For in  vitro cell line establishment, cells were seeded 
either onto gelatin-coated plate with hepatocyte culture 
medium (HCM) (Lonza, Basel, Switzerland) according 
to our previously optimized protocol [24], or ultra-low 
attachment plate with previously described serum-free 
and stem cell-promoting medium for spheroid formation 
[26] to increase the success rate. When spheroids formed, 
they were dissociated into disaggregated cells and seeded 
onto culture plate in AMEM supplemented with 10  % 
FBS. Cells attached and grew into adherent monolayer. 
The cells derived from patient #40 propagated and were 
passaged for more than 50 generations hereafter, and this 
cell line was designated as HCC40-CL. A split ratio of 
1:1–1:3 was applied in the early passages (passage 1–5), 
thereafter increased to 1:10. Cells were collected at dif-
ferent passages and put in freezing medium and stored in 
liquid nitrogen. After thawing, the cells could be propa-
gated in culture without noticeable change in morphol-
ogy and growth rate.
Immunohistochemical (IHC) staining
IHC staining was performed using the Dako Envision 
Plus System (Dako, Glostrup, Denmark) as previously 
described [27]. Tissue sections were stained with the 
mouse anti-human p53, rabbit anti-human HBV core 
antigen, mouse anti-human HBV surface antigen, AFP 
(Dako), Ki-67 (BD Biosciences), and equal amount of 
mouse or rabbit isotype controls (Sigma-Aldrich, St. 
Louis, MO).
Immunofluorescence staining and flow cytometric analysis
Cells were permeabilized with ice-cold 0.1 % saponin and 
then incubated with mouse anti-human albumin, AFP 
(R&D systems, Minneapolis,  MN), or equal amount of 
mouse IgG isotype (Sigma-Aldrich). Cells were washed 
with 0.1  % saponin and then stained with PE-conju-
gated anti-mouse IgG secondary antibody (Dako). After 
washings, cells were subject to flow cytometric analysis. 
Results were expressed as percentage of positive cells, 
after subtracting the non-specific background signal (iso-
type control).
Morphological examination and growth kinetics
Cells were routinely monitored using phase-contrast 
microscope and photographed. Cells from passage 20 
were studied to measure the population doubling time, 
which was assessed by 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay for 5 con-
secutive days.
Wound healing assay
Cells were seeded onto a 6-well culture plate and incu-
bated for 24 h. A wound was then made by scraping the 
cell monolayer with a 20 μL pipette tip. Cells were rinsed 
with PBS and cultured for 3 days. Cell movement toward 
the wound was observed under a phase-contrast micro-
scope and photographed every 24 h.
Short tandem repeat (STR) analysis
STR analysis was performed as previously described [24]. 
DNA samples of the HCC40-CL at passage 20, HCC40-
PDX at passage 10, primary tumor and the adjacent non-
tumor liver tissue from patient #40 were subjected to 
DNA fingerprinting analysis using the AmpF/STR Identi-
filer Plus PCR Amplification Kit (ThermoFisher Scientific 
Ltd., Waltham, MA).
Western blot analysis
Total protein was extracted with cell lysis buffer (Cell 
Signaling Technology, Boston, MA) in the presence of 
complete protease inhibitor cocktail (Roche, Mannheim, 
Germany) and separated in 8–10 % SDS PAGE gel. Pro-
teins were then electro-transferred onto polyvinylidene 
difluoride membranes, subsequently incubated with the 
mouse anti-human p53 (Dako), E-cadherin (BD Bio-
sciences), β-actin (Sigma-Aldrich), detected by horse-
radish peroxidase-labeled secondary antibodies, and 
visualized with Enhanced Chemiluminescence Western 
Blotting Detection Kit (Amersham Biosciences, Piscata-
way, NJ).
TP53 mutational analysis
DNA samples of the original tumor and the adjacent non-
tumor liver tissue from the patient #40, HCC40-CL cells 
and HCC40-PDX were subjected to direct DNA sequenc-
ing for exons 4-9 in p53 as previously described [24].
In vivo tumorigenicity in immunodeficient mice
The study protocol was approved by and performed in 
accordance with the Committee of the Use of Live Ani-
mals in Teaching and Research at the University of Hong 
Kong. HCC40-CL cells (passage 20) were harvested, 
washed, and resuspended in plain AMEM medium. 
1  ×  106 cells were inoculated subcutaneously into the 
right flank of each NOD/SCID mouse (4 weeks old). The 
mice were examined every week for the development of 
tumors and tumor-bearing mice were sacrificed when 
tumors were approximately 1 cm in diameters.
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Statistical analyzes
All data were expressed as mean values ± standard devi-
ation (SD) from at least three independent experiments. 
Differences between groups were assessed by the Stu-
dent’s t test. A probability (p) <0.05 was considered sig-
nificantly different. All analyzes were performed using 
the statistical software GraphPad Prism for Windows, 
Version 6.00 (GraphPad Software, CA).
Results
PDX and primary cell line establishment from fresh HCC 
tumor tissues
Fresh tumor tissues from 24 HCC patients were included 
for PDX and cell line establishment. We previously dem-
onstrated that GEP expression was positively correlated 
with the viability of freshly isolated hepatocytes and 
the success rate of primary culture establishment [24]. 
Therefore, GEP-expressing cells were sorted in order 
to increase the success rate of PDX and cell line estab-
lishment. GEP-enriched cells were then subject to both 
in vivo and in vitro establishment protocols. The in vitro 
spheroid formation and differentiation ability, and the 
in  vivo tumorigenicity of GEP-expressing cells were 
described [26], and the workflow of PDX and cell line 
establishment was illustrated in Additional file 1: Figure 
S1.
PDXs and cell lines were generated from the tumor 
specimens of 4 and 3 HCC cases, respectively. Among 
these successful cases, cells from HCC40 could generate 
both PDX and primary cell line successfully. Both models 
were able to propagate for over 10 generations and were 
then chosen for further characterization. The PDX and its 
matching cell line were designated as HCC40-PDX and 
HCC40-CL, respectively (Additional file 1: Figure S1).
Immunohistochemical characterization of HCC40‑PDX
IHC staining was performed to compare HCC40-PDX 
with the original tumor and adjacent non-tumor liver tis-
sue of patient #40. HBV surface antigen (HBsAg) was not 
detectable in the tumor and non-tumor liver tissue, nor 
in HCC40-PDX, corroborating that the patient is HBsAg 
seronegative. Nonetheless, strong HBV core antigen 
(HBcAg) was detectable in the majority of HCC cells in 
HCC40-PDX and the primary HCC specimen, and less 
intense in the adjacent non-tumor liver tissue. Active 
proliferation indicated by Ki-67 stain and moderate AFP 
expression was demonstrated in both the primary HCC 
specimen and HCC40-PDX (Fig. 1).
Phenotypic and functional characterization of HCC40‑CL 
cells
HCC40-CL cells were passaged for more than 50 gen-
erations since establishment. The cells grew as adherent 
monolayer with epithelial morphology and maintained 
consistent morphology along passages (Fig. 2a; Additional 
file  2: Figure S2). Flow cytometric analysis showed that 
98.2 % of the cells were albumin-positive, confirming that 
HCC40-CL cells were in the hepatic lineage. Besides, AFP 
positive cells by flow cytometry (Fig. 2b) corroborated the 
AFP staining pattern by immunohistochemistry (Fig. 1) and 
high serum AFP levels. Growth curve of HCC40-CL cells 
(passage 20) was shown in Fig. 2c. The population doubling 
time of HCC40-CL was approximately 43 h. Wound heal-
ing assay was performed to assess the migration ability of 
HCC40-CL cells. The cells started to migrate 1 day after the 
wound was made, and the wound healing was completed 
after 2 days (Fig. 2d). The migration ability of HCC40-CL 
cells echoed the histological observation that venous infil-
tration was present in the primary specimen.
Fig. 1 IHC characterization of HCC40-PDX. Paraffin-embedded tissue 
sections of adjacent non-tumor liver tissue and tumor specimen and 
HCC40-PDX were stained for HBV core antigen (HBcAg), HBV surface 
antigen (HBsAg), AFP, Ki-67, and the corresponding IgG controls. The 
tissue sections were then counterstained with haematoxylin. Magnifi-
cation: 200×, 400×
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Tumorigenicity and metastatic potential of HCC40‑CL cells 
in immunodeficient mice
HCC40-CL cells (1  ×  106) were inoculated subcutane-
ously into 4 NOD/SCID mice to assess its in vivo tumo-
rigenicity. About 4  weeks after injection, visible tumors 
developed in all mice at the site of inoculation (Fig. 3a), 
indicating that HCC40-CL cells were tumorigenic. 
Tumors were dissected, and H&E staining was per-
formed on the paraffin-embedded tissue section (Fig. 3a). 
The growth curve of tumors was shown in Fig. 3a (right 
panel). Besides, IHC analysis demonstrated the expres-
sion of HBcAg, AFP and Ki-67, but not HBsAg, in the 
HCC40-CL xenograft (Additional file 3: Figure S3). Such 
expression pattern was consistent with that observed in 
original tumor (Fig. 1).
To assess the metastatic potential, we measured the 
expression of E-cadherin, an adhesion molecule essential 
for stable cell connection and was known to be down-
regulated for metastasis [28–30]. Western blot analysis 
showed that E-cadherin protein, which was present in 
the patient’s non-tumor liver tissue, was down-regulated 
in the primary tumor specimen and HCC40-CL cells 
(Fig. 3b). HCC21 is a metastatic primary cell line estab-
lished by our group previously [24], and was included as a 
negative control for E-cadherin protein expression; while 
Hep3B, a non-metastatic HCC cell line, served as positive 
control. We further investigated the metastatic potential 
of HCC40-CL cells by injecting the cells (1 × 106) intra-
venously into NOD/SCID mice. Extensive metastases 
were observed in liver, kidney, lung, heart, spleen and 
pancreas (Fig. 3c).
STR profile analysis of HCC40‑PDX and HCC40‑CL cells
The DNA samples extracted from the primary tumor 
specimen and adjacent non-tumor liver tissue, HCC40-
PDX and HCC40-CL were subject to STR analysis. 
A total of 15 STR loci (CSF1P0, D2S1338, D3S1358, 
D5S818, D7S820, D8S1179, D13S317, D16S539, 
D18S51, D19S433, D21S11, FGA, TH01, TPOX, vWA) 
were co-amplified in each sample. AMLEO locus at the 
sex chromosomes was also examined. The data were 
analyzed and allele(s) of each locus were determined 
(Table 1). The STR profiles demonstrated that HCC40-
PDX and HCC40-CL were derived from the primary 
specimen HCC40. Notably, additional genetic aber-
rations were observed at loci CSF1P0 and D16S539 
in both HCC40-PDX and HCC40-CL along the 
establishment.
Fig. 2 Phenotypic and functional characterization of HCC40-CL. a Phase-contrast microscopy images of HCC40-CL cells at passages 20 (Magni-
fication: 100×, 200×). b Albumin and AFP levels of HCC40-CL cells were measured by flow cytometry. Percentages of albumin+ and AFP+ cells 
were indicated in the histograms. Dotted line: isotype control; Solid line: Albumin or AFP antibody. c Growth curve of HCC40-CL cells (passage 20) as 
determined by MTT. d Wound healing assay showing the migration ability of HCC40-CL cells. A wound was made by scraping the cell monolayer 
with a 20 μL pipette tip. Cell movement was photographed and observed under phase-contrast microscopy
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TP53 mutational analysis of HCC40‑PDX and HCC40‑CL 
cells
IHC staining showed that p53 nuclear accumulation in 
the primary tumor and HCC40-PDX, but not in adjacent 
non-tumor liver tissue (Fig.  4a). Western blot analysis 
demonstrated the presence of p53 protein in the primary 
tumor, HCC40-CL and HCC40-PDX, but not in non-
tumor adjacent liver tissue (Fig.  4b). Subsequent analy-
sis by DNA sequencing further consolidated a sporadic 
point mutation at codon 104 of exon 5 (CAG → CCG) 
(Gln → Pro) in the primary tumor specimen, and iden-
tical mutation was observed in both HCC40-CL and 
HCC40-PDX (Fig. 4c).
Discussion
PDX models are known to preserve most of the key bio-
logical properties of their primary tumors and remain 
stable across passages. These models are highly predic-
tive of clinical outcomes and therefore offer a potential 
for personalizing cancer treatments as well as assisting 
clinical trial designs [10–15]. The responses to targeted 
therapeutic agents have been reported to be highly cor-
related between PDX models and patients [10–16]. These 
models would be useful for testing the FDA-approved 
targeted drug sorafenib [2] and new target at preclini-
cal phase including GEP antibodies for growth inhibi-
tion and chemo-sensitization [31, 32]. In this study, we 
Fig. 3 Tumorigenicity and metastatic potential of HCC40-CL cells in NOD/SCID mice. a NOD/SCID mice inoculated subcutaneously with 1 × 106 
HCC40-CL cells at 8 weeks post-injection. The middle panel showed the corresponding xenograft tumor derived from HCC40-CL cells (scale bar 
10 mm) and H&E staining of the paraffin-embedded tissue section (Magnification: 200×, 400×). The right panel showed the growth curve of 
HCC40-CL cell-derived xenografts (n = 4). b Protein expression of E-cadherin in HCC21 (negative control), Hep3B (positive control), adjacent non-
tumor liver tissue and tumor specimen from patient HCC40, and HCC40-CL cells. β-actin served as loading control. c HCC40-CL cells were injected 
intravenously into NOD/SCID mice. H&E staining showed extensive metastases observed in the liver, kidney, lung, heart, spleen and pancreas of the 
mice
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established a PDX model from a patient with early staged 
and moderately differentiated HCC. Our PDX model, 
HCC40-PDX, showed remarkable congruence in the bio-
logical phenotypes and molecular details of the primary 
tumor. The models were authenticated by STR analysis, 
and both could be cryopreserved, so that stable supply of 
the models for drug and other assays could be ensured. 
It was demonstrated that serial propagation in mice did 
not significantly change the biological characteristics of 
xenograft tumors. Studies that compared the response to 
drug treatments of PDXs from different passages demon-
strated stable response rates across generations, further 
supporting the phenotypic stability of these models [11, 
33] and making them a useful tool for studying pathogen-
esis of HCC and its therapeutic strategy.
In addition to PDX models, their matching cell lines 
are also valuable tools as they allow high throughput 
drug screening and genetic manipulation for in depth 
mechanistic study. Here, we established and character-
ized a matching cell line from the same patient from 
which HCC40-PDX was derived. The matching cell 
line, HCC40-CL, was authenticated, characterized and 
showed congruence in the p53 mutational status with 
the primary tumor. Importantly, this cell line possessed 
metastatic ability. HCC has been reported with high inci-
dence of metastasis, which is a major obstacle to HCC 
treatment [34]. The underlying mechanism of metastasis 
in HCC is not well-characterized, which is probably due 
to the lack of appropriate models for the related studies. 
Here, we showed that intravenous injection of HCC40-
CL led to extensive metastases in immunocompromised 
mice, indicating the metastatic ability of the cells. In cur-
rent study, we assessed the expression of E-cadherin in 
the original tumor and liver specimens, and HCC40-CL 
cells. E-cadherin is a cell adhesion molecule essential for 
establishing stable intercellular adherent junctions, and 
its down-regulation is associated with infiltrative growth 
and metastasis in various cancers including HCC [35, 
36]. We showed that E-cadherin in original tumor speci-
men was reduced when compared to the adjacent non-
tumor liver tissue, and the down-regulation was retained 
in HCC40-CL cells, implying a metastatic potential of 
in both original tumor specimen and HCC40-CL cells. 
For HCC40-PDX subcutaneous inoculation, however, 
no metastasis was observed in the recipient mice. Inde-
pendent research groups have reported that subcutane-
ously transplanted tumors were less prone to metastasize 
either regionally or distally [37, 38]. Orthotopic implanta-
tions were shown to form vascularized xenografts more 
readily and therefore higher frequency of spontaneous 
distant metastasis could be observed [38]. Besides, the 
organ site corresponding to the tumor origin would allow 
the tumor to behave more similarly to the original tumor. 
Therefore, further investigation on the metastatic poten-
tial of HCC40-PDX should be performed using ortho-
topic model.
p53 is frequently mutated and overexpressed in HCC 
[39]. p53 alterations are reported to correlate with the 
aggressiveness of HCC, including tumor differentiation, 
vascular invasion and tumor stage [40, 41]. Missense 
mutations leading to amino acid substitutions are com-
mon mutation in TP53 [42]. Here, we showed a point 
mutation in the TP53 gene at codon 104 of exon 5 (CAG 
→ CCG) (Gln → Pro) in tumor specimen, and the muta-
tion was retained in both HCC40-CL cells and HCC40-
PDX. This mutation has not been reported in HCC 
previously. However, this mutation might result in the 
presence of aberrant protein with increased stability and 
nuclear accumulation in the cells, similarly as other p53 
mutations [42]. This is supported by the strong nuclear 
protein expression of p53 in HCC40-PDX and the pri-
mary tumor specimen, when compared to the adjacent 
non-tumor liver tissue (Fig. 4a).
In current study, disaggregated tumor cells from 
HCC patients were sorted for hepatic cancer stem cell 
marker GEP to increase the cell viability and facili-
tate the PDX and cell line establishment. We previ-
ously showed that GEP-expressing cells possess CSC 
Table 1 STR profiles of  adjacent non-tumor liver tissue 
and tumor specimen, HCC40-PDX and HCC40-CL
Differences were italicized
Locus Adjacent non‑
tumor
Tumor HCC40‑PDX HCC40‑CL
D8S1179 13 13 13 13
D21S11 28, 32.2 28, 32.2 28, 32.2 28, 32.2
D7S820 10, 11 10, 11 10, 11 10, 11
CSF1PO 10, 11 10, 11 10, 11, 12 10, 11, 12
D3S1358 15, 16 15, 16 15, 16 15, 16
TH01 6, 9 6, 9 6, 9 6, 9
D13S317 8, 9 8, 9 8, 9 8, 9
D16S539 10, 12 10, 12 12 12
D2S1338 18, 21 18, 21 18, 21 18, 21
D19S433 13, 15 13, 15 13, 15 13, 15
vWA 14, 19 14, 19 14, 19 14, 19
TPOX 8, 9 8, 9 8, 9 8, 9
D18S51 17, 18 17, 18 17, 18 17, 18
AMELOGENIN X, Y X, Y X, Y X, Y
D5S818 11, 13 11, 13 11, 13 11, 13
FGA 22, 25 22, 25 22, 25 22, 25
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properties in HCC [23]. Asymmetric cell division is a 
defining CSC property, which enables them to simulta-
neously perpetuate themselves i.e. self-renew, and gener-
ate differentiated progenies [43]. Indeed, we showed in 
a separate study that transplantation of sorted GEPhigh 
cells (GEP  +  cells:  >80  %) into immunocompromised 
mice could generate heterogeneous tumor mass consist-
ing of both GEP+ and GEP− cells, in which GEP levels 
were found to return to the level of the original tumors 
from which they were derived [26]. Similar phenome-
non has also been observed in other HCC CSC markers 
such as CD24 and CD133 [44, 45]. Therefore, although 
GEP-expressing cells were enriched for PDX and cell line 
establishment to increase success rate, their levels would 
return to recapitulate those of the original tumors, and 
would not cause bias to the cellular composition due to 
the CSC nature of GEP-expressing cells.
Conclusions
We have established a PDX model and the matching pri-
mary cell line from an early-staged and moderately dif-
ferentiated HCC. Our newly established models will not 
only aid in the development of new therapeutic strate-
gies, but also in gaining insight in the mechanisms under-
lying how the tumors respond to therapeutic agents. This, 
in turn, can shed light on the molecular pathogenesis of 
Fig. 4 TP53 mutational analysis in original tumor and adjacent non-tumor liver tissue, HCC40-CL and HCC40-PDX. a IHC staining of p53 in adjacent 
non-tumor liver tissue and tumor specimen, and HCC40-PDX. Magnification: 400×. b Expression of p53 protein in Hep3B (p53 null), primary tumor 
specimen, adjacent non-tumor liver tissue, HCC40-CL and HCC40-PDX by western blot. β-actin served as loading control. c Sequencing analysis of 
TP53 gene revealed a point mutation at codon 104 of exon 5 (CAG → CCG) (Gln → Pro) in tumor specimen, HCC40-CL, and HCC40-PDX, but not in 
adjacent non-tumor liver tissue
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HCC. Future work includes expanding the pool of PDXs, 
together with their matching cell lines, to examine the 
heterogeneous HCC.
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